Archive for the ‘athletic’ tag
AzaSite for bacterial conjunctivitis
Click on the images to see the full-sized ads and get all the info on AdPharm.
More antibiotics’ ads on AdPharm here
Barrier surgical gowns
Barrier Surgical Gowns
New barrier surgical gowns.
Advanced flexibility that lets you perform to your personal best.

Brand name: Barrier
Generic name/category: Surgical gowns
Company: Mölnlycke Health Care
Country/Market: UK, Europe
Indication(s)/use: Surgery
Target: Healthcare Professionals (HCP) / Trade
Tagline: No compromise in security
Medium: Print ad
Size/duration: double-page spread
Publication/Aired: 2009
To see all of this brand’s ads on AdPharm, click here
Claritin – climber
Why choose an allergy medicine that won't last as long as you do?
New Claritin 12-hour
Introducing Claritin 12-hour, the only 12-hour allergy medicine that relieves your worst symptoms without making you drowsy.

Loratadine is an antihistamine drug used to treat allergies, and marketed for its non-sedating properties. It is marketed by Schering-Plough and Shionogi in Japan under several trade names such as Claritin, Claritin-D, Claritine, Clarityn, Clarityne or Fristamin depending on the market; by Cadila as Lorfast; by Lek as Lomilan or Flonidan; by Sandoz as Symphoral; by Ranbaxy as Roletra; by Pliva as Rinolan; by Teva as AllergyX; by Wyeth as Alavert; and by Pharma International as Tidilor. It is also available as a generic. In a version marketed as Claritin-D or Clarinase, loratadine is combined with pseudoephedrine, a decongestant; this makes it somewhat useful for colds as well as allergies, but adds potential side-effects of insomnia, nervousness, and anxiety.
It is considered a second generation agent.

Brand name: Claritin
Generic name/category: Loratadine, antihistamine, H1 receptor antagonists, Carbamates
Company: Schering-Plough
Country/Market: USA, North America
Indication(s)/use: allergies
Target: Consumers (DTC)
Tagline: Live Claritin Clear. Indoors and Out.
Medium: Print ad
Size/duration: single-page
Publication/Aired: Reader's Digest – September 2009
To see all of this brand's ads on AdPharm, click here
2 views
Aug 28, 2009
Visit AdPharm.net for more pharmaceutical ads
Pfizer
Outoa kipua, johon mik?€?€n ei tunnu auttavan?
Polttelua, pistely?€ tai alasel?€st?€ pohkeeseen s?€teilev?€?€ kipua. Joskus pelkk?€ vaatteen hipaisu voi tuntua kivuliaalta. Yhteist?€ n?€ille oudoille kivuntuntemuksille on se, ett?€ yleisesti k?€ytetyist?€ kipul?€?€kkeist?€ ei ole mit?€?€n apua.
Edell?€ kuvatut oireet voivat viitata hermovauriokipuun eli neuropaattiseen kipuun.
Onneksi sit?€ voidaan hoitaa. Kysy l?€?€k?€rilt?€si tai katso lis?€tietoja osoitteessa www.neuropaattinenkipu.fi
Jonkun on oltava ensimm?€inen.
Strange pain, for which nothing seems to help?
Burning, tingling, or pain radiating to lower back. Sometimes touching a simple garment may seem painful. What these strange pains, the usual pain medicines does not seem to be of any help.
Described above symptoms may indicate nerve damage causing pain or neuropathic pain.
Fortunately, it can be treated. Ask your doctor or get more details, visit www.neuropaattinenkipu.fi
Someone has to be the first.

Brand name: Pfizer
Generic name/category: corporate ad, disease awareness
Company: Pfizer
Country/Market: Finland, Europe
Indication(s)/use: neuropathic pain
Target: Consumers (DTC)
Tagline: Jonkun on oltava ensimm?€inen – Someone has to be the first
Medium: Print ad
Size/duration: double-page spread
Publication/Aired: Kauneus And Terveys – December 2006
To see all of this brand's ads on AdPharm, click here
0 views
Aug 27, 2009
Visit AdPharm.net for more pharmaceutical ads
Topicort
There’s a lot of flexibility in Topicort
Multiple potencies
Choice of 3 vehicles
Propylene Glycol-free
Preservative-free
Class “C” corticosteroid
Brand name: Topicort
Generic name/category: Desoximetasone, corticosteroid
Company: Taro Pharma
Country/Market: USA, North America
Indication(s)/use: dermatose, inflammation
Target: Healthcare Professionals (HCP) / Trade
Tagline: Multiple choices. One solution
Publication: Dermatology Times May 2009




